Zepbound vials get cheaper and reach higher doses
Lilly lowered the vial price for the starting dose and added 7.5 mg and 10 mg vials, with the best price tied to refilling on time.
Who feels it
-
Patients
Rethink
Higher doses now come in vials, but the lowest price depends on refilling within a set window.
-
Prescribers
Adjust
Patients who needed higher doses can now stay on a cash vial.
-
Sellers
Adjust
Compounders lose the argument that higher doses were only available from them.
-
Pharmacies
Worth knowing
Still mostly a direct-to-patient channel.
-
Payers
Worth knowing
Strengthens the cheaper cash route for people their plans exclude.
New prices
Lilly cut the self-pay price of the 2.5 mg vial to $349 and the 5 mg vial to $499. It also added 7.5 mg and 10 mg vials, sold at $499 a month for people who refill on time.
Why the refill window
Tying the lowest price to on-time refills rewards staying on treatment. People who stop and restart pay more for that dose.
What it means
Until this point, people who needed higher doses but had no insurance had few options except compounded copies. With higher-dose vials, the maker’s own product covered most of the dose ladder.
Still missing
The vials remained cash only, and the top doses were still pen only at the time of this change.
Source Eli Lilly press release, 25 February 2025
Spotted an error? Tell us through the contact form; we follow the corrections policy.
